127 results on '"Kasenda, B."'
Search Results
2. Targeting immunoliposomes to EGFR-positive glioblastoma
3. 50MO Adoptive cell therapy with tumor-infiltrating lymphocytes in combination with nivolumab in patients with advanced melanoma
4. 122P Molecular testing, treatment, and response of patients with advanced solid tumors harboring an NTRK gene fusion: Second interim results of the REALTRK registry
5. CONSOLIDATIVE HCT‐ASCT IS SUPERIOR TO NON‐MYELOABLATIVE CHEMO‐IMMUNOTHERAPY IN NEWLY‐DIAGNOSED PCNSL ‐ UPDATED RESULTS OF THE RANDOMIZED PHASE III MATRIX/IELSG43 TRIAL
6. 67P Molecular testing and treatment of patients with advanced solid tumors harboring an NTRK gene fusion: Interim results of the REALTRK registry
7. High-dose chemotherapy with autologous haematopoietic stem cell support for relapsed or refractory primary CNS lymphoma: a prospective multicentre trial by the German Cooperative PCNSL study group
8. 70P Genetic alterations and immune cell infiltration with potential impact on PD-(L)1 targeted treatment in various cancer entities: Biobank research project of the INFINITY registry
9. High-dose thiotepa-based chemotherapy with autologous stem cell support in elderly patients with primary central nervous system lymphoma: a European retrospective study
10. 76P Second interim analysis of INFINITY: A registry on decision making and clinical impact of biomarker-driven precision oncology in routine clinical practice
11. Zweite Interimsanalyse zu INFINITY : ein Register zur Entscheidungsfindung in der Biomarker-basierten Präzisionsonkologie und deren klinische Bedeutung
12. 31P Molecular testing, treatment and outcome of patients with advanced solid tumors harboring a NTRK1, NTRK2 or NTRK3 gene fusion: Study design and first results of the REALTRK registry
13. Planning and reporting of quality-of-life outcomes in cancer trials
14. Outcomes for HIV-positive patients with primary central nervous system lymphoma after high-dose chemotherapy and auto-SCT
15. First-line treatment and outcome of elderly patients with primary central nervous system lymphoma (PCNSL)—a systematic review and individual patient data meta-analysis
16. First interim analysis of INFINITY : A registry on decision making and clinical impact of biomarker-driven precision oncology in routine clinical practice
17. Reimbursement Reality for Off-label use in Swiss Cancer Care – A systematic empirical investigation
18. First results from INFINITY - A registry on decision making and clinical impact of biomarker-driven precision oncology in routine clinical practice
19. What proportion of ethically approved randomised clinical trials can be found in a trial registry?
20. Outcomes for HIV-positive patients with primary central nervous system lymphoma after high-dose chemotherapy and auto-SCT
21. Reimbursement reality for off-label use in cancer care: A systematic empirical investigation
22. Contrasting Evidence to Reimbursement Reality for Off-label use (OLU) of Drug Treatments in Cancer Care – Rationale and Design of the CEIT-OLU-project
23. OFF-LABEL USE IN LYMPHOMA PATIENTS IN SWITZERLAND
24. BICENTRIC PILOT STUDY ON AGE-ADAPTED HIGH-DOSE CHEMOTHERAPY AND AUTOLOGOUS STEM CELL TRANSPLANT IN NEWLY DIAGNOSED PRIMARY CNS LYMPHOMA PATIENTS > 65 YEARS - MARiTA TRIAL
25. 1630O - Reimbursement reality for off-label use in cancer care: A systematic empirical investigation
26. 3-weekly or weekly cisplatin concurrently with radiotherapy for patients with locally advanced squamous cell carcinoma of the head and neck: A multicentre, retrospective analysis
27. High-dose methotrexate-based immuno-chemotherapy for elderly primary CNS lymphoma patients (PRIMAIN study)
28. Dynamics of neutrophil to lymphocyte ratio (NLR) predict effectiveness of PD1/PDL1 inhibition
29. Serum lactate dehydrogenase as an early marker for outcome in patients treated with anti-PD-1 therapy in metastatic melanoma
30. Correction to: Planning and reporting of quality-of-life outcomes in cancer trials
31. Prognosis after high-dose chemotherapy followed by autologous stem-cell transplantation as first-line treatment in primary CNS lymphoma—a long-term follow-up study
32. 1065P - 3-weekly or weekly cisplatin concurrently with radiotherapy for patients with locally advanced squamous cell carcinoma of the head and neck: A multicentre, retrospective analysis
33. High-dose methotrexate-based immuno-chemotherapy for elderly primary CNS lymphoma patients (PRIMAIN study)
34. Prognostic value of KRAS G12C in advanced non-small cell lung cancer with high PD-L1 expression treated with upfront immunotherapy: a systematic review and meta-analysis.
35. Melanoma Clonal Heterogeneity Leads to Secondary Resistance after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes.
36. Quantifying bias due to missing data in quality of life surveys of advanced-stage cancer patients.
37. High-dose chemotherapy and autologous haematopoietic stem-cell transplantation in older, fit patients with primary diffuse large B-cell CNS lymphoma (MARTA): a single-arm, phase 2 trial.
38. The evidence base of US Food and Drug Administration approvals of novel cancer therapies from 2000 to 2020.
39. The INFINITY study protocol: a retrospective cohort study on decision making and clinical impact of biomarker-driven precision oncology in routine clinical practice.
40. Completion and publication of clinical trials in a cooperative group: a cohort study of trials of the Swiss Group for Clinical Cancer Research (SAKK).
41. European Association of Neuro-Oncology (EANO) guidelines for treatment of primary central nervous system lymphoma (PCNSL).
42. Targeting cancer glycosylation repolarizes tumor-associated macrophages allowing effective immune checkpoint blockade.
43. Characteristics and survival of patients with cancer with intended off-label use-a cohort study.
44. Reporting quality of clinical trial protocols: a repeated cross-sectional study about the Adherence to SPIrit Recommendations in Switzerland, CAnada and GErmany (ASPIRE-SCAGE).
45. Nonregistration, discontinuation, and nonpublication of randomized trials: A repeated metaresearch analysis.
46. Reporting quality of trial protocols improved for non-regulated interventions but not regulated interventions: A repeated cross-sectional study.
47. Evaluation of Planned Subgroup Analysis in Protocols of Randomized Clinical Trials.
48. Association of Supporting Trial Evidence and Reimbursement for Off-Label Use of Cancer Drugs.
49. Clinical Trial Evidence Supporting US Food and Drug Administration Approval of Novel Cancer Therapies Between 2000 and 2016.
50. Rationale and design of repeated cross-sectional studies to evaluate the reporting quality of trial protocols: the Adherence to SPIrit REcommendations (ASPIRE) study and associated projects.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.